Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Childress back at HELP: Mark Childress rejoins the Senate Health, Education, Labor and Pensions Committee as senior adviser for national health reform. He briefly was chief of staff at the Department of Health and Human Services, one of the staff selections of former HHS Secretary-nominee Tom Daschle. But his departure was expected after Daschle withdrew his nomination. A member of the Obama transition team, Childress left a partnership at Foley Hoag to take the HHS appointment; he had been Daschle's chief counsel and policy director from 2000 to 2005. This will be Childress' second tour at the Senate panel, having worked there from 1989 to 1995 as chief counsel. At HHS, it appears that Laura Petrou, also a former Daschle aide, will step in as chief of staff, at least temporarily

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel